Printer Friendly

ISIS PHARMACEUTICALS AWARDED NEARLY $1 MILLION IN FEDERALLY SPONSORED RESEARCH PROGRAMS

 CARLSBAD, Calif., Aug. 17 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIP) today announced that it has been awarded nearly $1 million in Phase II SBIR grants to continue its work on characterizing antisense oligonucleotides against replication of a human papillomavirus (the cause of genital warts), and the Herpes simplex virus.
 Isis announced a notice of award from the National Cancer Institute (NCI) for "Oligonucleotides as inhibitors of papillomaviruses" in the amount of $500,000 for a two-year study period. The award will allow Isis to gain additional insights into the life cycle of the papillomavirus, and complements the company's work being undertaken in Phase II of human clinical trials for ISIS 2105, a oligonucleotide-based drug that is being tested as a treatment for human genital warts.
 The second award, "Antisense inhibitors of herpes simplex virus replication," was awarded by the National Institute for Allergies and Infectious Diseases (NIAID) in the amount of $429,974 for a 27-month investigation to characterize further antisense oligonucleotides that were shown to exhibit potent antiviral activity against HSV-1 in the first phase of the study. Phase II research will be to characterize these compounds in cell culture systems and to evaluate their activity in relevant animal models of HSV-1-induced disease.
 Isis Pharmaceuticals, located in Northern San Diego County, is engaged in the discovery and development of novel oligonucleotide-based human therapeutic compounds. Isis has a broad oligonucleotide research program and multiple compounds in preclnical development. The company's first oligonucleotide-based drug for human genital warts, ISIS 2105, is in pivotal Phase II clinical trials.
 -0- 8/17/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., of Isis Pharmaceuticals, 619-931-9200; or Lorraine Ruff of Stoorza, Ziegaus & Metzger, 619-236-1332, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals Inc. ST: California IN: MTC SU:

BP -- SD004 -- 3583 08/17/93 13:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1993
Words:300
Previous Article:PENN POWER ASKS PUBLIC WELFARE DEPARTMENT TO KEEP LOW-INCOME CUSTOMERS ELIGIBLE FOR EMERGENCY ASSISTANCE
Next Article:MAIN ST. & MAIN INC. ANNOUNCES GRAND OPENING OF SEOUL T.G.I. FRIDAY'S IN SEOUL, KOREA
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters